nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfentanil—ALB—multiple sclerosis	0.346	1	CbGaD
Alfentanil—ALB—Prednisone—multiple sclerosis	0.0481	0.0968	CbGbCtD
Alfentanil—ABCB1—Methylprednisolone—multiple sclerosis	0.0415	0.0836	CbGbCtD
Alfentanil—CYP3A4—Fingolimod—multiple sclerosis	0.0386	0.0777	CbGbCtD
Alfentanil—CYP3A7—Dexamethasone—multiple sclerosis	0.0322	0.0648	CbGbCtD
Alfentanil—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0322	0.0648	CbGbCtD
Alfentanil—ABCB1—Mitoxantrone—multiple sclerosis	0.0303	0.061	CbGbCtD
Alfentanil—ABCB1—Betamethasone—multiple sclerosis	0.027	0.0544	CbGbCtD
Alfentanil—ABCB1—Prednisolone—multiple sclerosis	0.0267	0.0536	CbGbCtD
Alfentanil—ABCB1—Prednisone—multiple sclerosis	0.0252	0.0506	CbGbCtD
Alfentanil—CYP3A4—Methylprednisolone—multiple sclerosis	0.0249	0.0501	CbGbCtD
Alfentanil—CYP3A5—Dexamethasone—multiple sclerosis	0.0241	0.0486	CbGbCtD
Alfentanil—ALB—Methotrexate—multiple sclerosis	0.0241	0.0486	CbGbCtD
Alfentanil—CYP3A4—Triamcinolone—multiple sclerosis	0.0189	0.038	CbGbCtD
Alfentanil—CYP3A4—Mitoxantrone—multiple sclerosis	0.0182	0.0365	CbGbCtD
Alfentanil—CYP3A4—Betamethasone—multiple sclerosis	0.0162	0.0326	CbGbCtD
Alfentanil—CYP3A4—Prednisolone—multiple sclerosis	0.016	0.0321	CbGbCtD
Alfentanil—ABCB1—Dexamethasone—multiple sclerosis	0.0157	0.0316	CbGbCtD
Alfentanil—CYP3A4—Prednisone—multiple sclerosis	0.0151	0.0303	CbGbCtD
Alfentanil—ABCB1—Methotrexate—multiple sclerosis	0.0126	0.0254	CbGbCtD
Alfentanil—CYP3A4—Dexamethasone—multiple sclerosis	0.00942	0.0189	CbGbCtD
Alfentanil—Bradycardia—Prednisolone—multiple sclerosis	0.000409	0.00311	CcSEcCtD
Alfentanil—Hypotension—Azathioprine—multiple sclerosis	0.000402	0.00306	CcSEcCtD
Alfentanil—Vision blurred—Mitoxantrone—multiple sclerosis	0.000402	0.00305	CcSEcCtD
Alfentanil—Cardiac arrest—Prednisone—multiple sclerosis	0.000401	0.00305	CcSEcCtD
Alfentanil—Hypersensitivity—Cladribine—multiple sclerosis	0.00039	0.00296	CcSEcCtD
Alfentanil—Epistaxis—Triamcinolone—multiple sclerosis	0.000388	0.00295	CcSEcCtD
Alfentanil—Visual impairment—Prednisolone—multiple sclerosis	0.000387	0.00294	CcSEcCtD
Alfentanil—Asthenia—Cladribine—multiple sclerosis	0.00038	0.00289	CcSEcCtD
Alfentanil—Bradycardia—Triamcinolone—multiple sclerosis	0.000376	0.00286	CcSEcCtD
Alfentanil—Bradycardia—Methylprednisolone—multiple sclerosis	0.000375	0.00285	CcSEcCtD
Alfentanil—Pruritus—Cladribine—multiple sclerosis	0.000374	0.00285	CcSEcCtD
Alfentanil—Visual disturbance—Methotrexate—multiple sclerosis	0.000372	0.00283	CcSEcCtD
Alfentanil—Cough—Mitoxantrone—multiple sclerosis	0.000372	0.00283	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000371	0.00282	CcSEcCtD
Alfentanil—Convulsion—Mitoxantrone—multiple sclerosis	0.000369	0.00281	CcSEcCtD
Alfentanil—Hypertension—Mitoxantrone—multiple sclerosis	0.000368	0.0028	CcSEcCtD
Alfentanil—Anaphylactoid reaction—Methotrexate—multiple sclerosis	0.000364	0.00277	CcSEcCtD
Alfentanil—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000362	0.00275	CcSEcCtD
Alfentanil—Arrhythmia—Prednisolone—multiple sclerosis	0.000359	0.00273	CcSEcCtD
Alfentanil—Visual impairment—Methylprednisolone—multiple sclerosis	0.000355	0.0027	CcSEcCtD
Alfentanil—Feeling abnormal—Azathioprine—multiple sclerosis	0.000354	0.0027	CcSEcCtD
Alfentanil—Confusional state—Mitoxantrone—multiple sclerosis	0.000351	0.00267	CcSEcCtD
Alfentanil—Dizziness—Cladribine—multiple sclerosis	0.00035	0.00266	CcSEcCtD
Alfentanil—Erythema—Prednisolone—multiple sclerosis	0.00035	0.00266	CcSEcCtD
Alfentanil—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000348	0.00265	CcSEcCtD
Alfentanil—Eye disorder—Methylprednisolone—multiple sclerosis	0.000344	0.00262	CcSEcCtD
Alfentanil—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000342	0.0026	CcSEcCtD
Alfentanil—Bradycardia—Dexamethasone—multiple sclerosis	0.000341	0.00259	CcSEcCtD
Alfentanil—Bradycardia—Betamethasone—multiple sclerosis	0.000341	0.00259	CcSEcCtD
Alfentanil—Body temperature increased—Azathioprine—multiple sclerosis	0.00034	0.00259	CcSEcCtD
Alfentanil—Tachycardia—Mitoxantrone—multiple sclerosis	0.000339	0.00258	CcSEcCtD
Alfentanil—Skin disorder—Mitoxantrone—multiple sclerosis	0.000338	0.00257	CcSEcCtD
Alfentanil—Vomiting—Cladribine—multiple sclerosis	0.000336	0.00256	CcSEcCtD
Alfentanil—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.000336	0.00256	CcSEcCtD
Alfentanil—Angiopathy—Methylprednisolone—multiple sclerosis	0.000334	0.00254	CcSEcCtD
Alfentanil—Rash—Cladribine—multiple sclerosis	0.000334	0.00254	CcSEcCtD
Alfentanil—Dermatitis—Cladribine—multiple sclerosis	0.000333	0.00254	CcSEcCtD
Alfentanil—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000333	0.00253	CcSEcCtD
Alfentanil—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000332	0.00253	CcSEcCtD
Alfentanil—Headache—Cladribine—multiple sclerosis	0.000331	0.00252	CcSEcCtD
Alfentanil—Arrhythmia—Triamcinolone—multiple sclerosis	0.00033	0.00251	CcSEcCtD
Alfentanil—Vision blurred—Prednisolone—multiple sclerosis	0.000329	0.00251	CcSEcCtD
Alfentanil—Arrhythmia—Methylprednisolone—multiple sclerosis	0.000329	0.0025	CcSEcCtD
Alfentanil—Hypotension—Mitoxantrone—multiple sclerosis	0.000325	0.00247	CcSEcCtD
Alfentanil—Visual impairment—Betamethasone—multiple sclerosis	0.000323	0.00246	CcSEcCtD
Alfentanil—Visual impairment—Dexamethasone—multiple sclerosis	0.000323	0.00246	CcSEcCtD
Alfentanil—Mental disorder—Methylprednisolone—multiple sclerosis	0.000323	0.00246	CcSEcCtD
Alfentanil—Erythema—Triamcinolone—multiple sclerosis	0.000321	0.00245	CcSEcCtD
Alfentanil—Erythema—Methylprednisolone—multiple sclerosis	0.000321	0.00244	CcSEcCtD
Alfentanil—Hypersensitivity—Azathioprine—multiple sclerosis	0.000317	0.00241	CcSEcCtD
Alfentanil—Nausea—Cladribine—multiple sclerosis	0.000314	0.00239	CcSEcCtD
Alfentanil—Eye disorder—Betamethasone—multiple sclerosis	0.000313	0.00238	CcSEcCtD
Alfentanil—Eye disorder—Dexamethasone—multiple sclerosis	0.000313	0.00238	CcSEcCtD
Alfentanil—Somnolence—Mitoxantrone—multiple sclerosis	0.000309	0.00235	CcSEcCtD
Alfentanil—Loss of consciousness—Prednisolone—multiple sclerosis	0.000307	0.00234	CcSEcCtD
Alfentanil—Angiopathy—Dexamethasone—multiple sclerosis	0.000304	0.00231	CcSEcCtD
Alfentanil—Angiopathy—Betamethasone—multiple sclerosis	0.000304	0.00231	CcSEcCtD
Alfentanil—Convulsion—Prednisolone—multiple sclerosis	0.000303	0.0023	CcSEcCtD
Alfentanil—Hypertension—Prednisolone—multiple sclerosis	0.000302	0.0023	CcSEcCtD
Alfentanil—Fatigue—Mitoxantrone—multiple sclerosis	0.0003	0.00228	CcSEcCtD
Alfentanil—Arrhythmia—Dexamethasone—multiple sclerosis	0.000299	0.00228	CcSEcCtD
Alfentanil—Arrhythmia—Betamethasone—multiple sclerosis	0.000299	0.00228	CcSEcCtD
Alfentanil—Pain—Mitoxantrone—multiple sclerosis	0.000297	0.00226	CcSEcCtD
Alfentanil—Bradycardia—Prednisone—multiple sclerosis	0.000297	0.00226	CcSEcCtD
Alfentanil—Erythema—Dexamethasone—multiple sclerosis	0.000292	0.00222	CcSEcCtD
Alfentanil—Erythema—Betamethasone—multiple sclerosis	0.000292	0.00222	CcSEcCtD
Alfentanil—Connective tissue disorder—Prednisone—multiple sclerosis	0.000287	0.00218	CcSEcCtD
Alfentanil—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000287	0.00218	CcSEcCtD
Alfentanil—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000285	0.00217	CcSEcCtD
Alfentanil—Dizziness—Azathioprine—multiple sclerosis	0.000284	0.00216	CcSEcCtD
Alfentanil—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000283	0.00215	CcSEcCtD
Alfentanil—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000282	0.00214	CcSEcCtD
Alfentanil—Cough—Triamcinolone—multiple sclerosis	0.00028	0.00213	CcSEcCtD
Alfentanil—Convulsion—Triamcinolone—multiple sclerosis	0.000279	0.00212	CcSEcCtD
Alfentanil—Tachycardia—Prednisolone—multiple sclerosis	0.000278	0.00212	CcSEcCtD
Alfentanil—Convulsion—Methylprednisolone—multiple sclerosis	0.000278	0.00211	CcSEcCtD
Alfentanil—Hypertension—Triamcinolone—multiple sclerosis	0.000278	0.00211	CcSEcCtD
Alfentanil—Hypertension—Methylprednisolone—multiple sclerosis	0.000277	0.00211	CcSEcCtD
Alfentanil—Urticaria—Mitoxantrone—multiple sclerosis	0.000276	0.0021	CcSEcCtD
Alfentanil—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000276	0.0021	CcSEcCtD
Alfentanil—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000275	0.00209	CcSEcCtD
Alfentanil—Vomiting—Azathioprine—multiple sclerosis	0.000273	0.00208	CcSEcCtD
Alfentanil—Eye disorder—Prednisone—multiple sclerosis	0.000273	0.00207	CcSEcCtD
Alfentanil—Drowsiness—Methotrexate—multiple sclerosis	0.000272	0.00207	CcSEcCtD
Alfentanil—Rash—Azathioprine—multiple sclerosis	0.000271	0.00206	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000271	0.00206	CcSEcCtD
Alfentanil—Dermatitis—Azathioprine—multiple sclerosis	0.000271	0.00206	CcSEcCtD
Alfentanil—Headache—Azathioprine—multiple sclerosis	0.000269	0.00205	CcSEcCtD
Alfentanil—Angiopathy—Prednisone—multiple sclerosis	0.000265	0.00201	CcSEcCtD
Alfentanil—Confusional state—Methylprednisolone—multiple sclerosis	0.000264	0.00201	CcSEcCtD
Alfentanil—Immune system disorder—Prednisone—multiple sclerosis	0.000264	0.002	CcSEcCtD
Alfentanil—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000262	0.002	CcSEcCtD
Alfentanil—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000262	0.00199	CcSEcCtD
Alfentanil—Arrhythmia—Prednisone—multiple sclerosis	0.000261	0.00198	CcSEcCtD
Alfentanil—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000257	0.00195	CcSEcCtD
Alfentanil—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000256	0.00195	CcSEcCtD
Alfentanil—Loss of consciousness—Betamethasone—multiple sclerosis	0.000256	0.00195	CcSEcCtD
Alfentanil—Epistaxis—Methotrexate—multiple sclerosis	0.000256	0.00195	CcSEcCtD
Alfentanil—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000256	0.00195	CcSEcCtD
Alfentanil—Tachycardia—Triamcinolone—multiple sclerosis	0.000256	0.00195	CcSEcCtD
Alfentanil—Mental disorder—Prednisone—multiple sclerosis	0.000256	0.00194	CcSEcCtD
Alfentanil—Nausea—Azathioprine—multiple sclerosis	0.000255	0.00194	CcSEcCtD
Alfentanil—Tachycardia—Methylprednisolone—multiple sclerosis	0.000255	0.00194	CcSEcCtD
Alfentanil—Skin disorder—Methylprednisolone—multiple sclerosis	0.000254	0.00193	CcSEcCtD
Alfentanil—Erythema—Prednisone—multiple sclerosis	0.000254	0.00193	CcSEcCtD
Alfentanil—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000254	0.00193	CcSEcCtD
Alfentanil—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000253	0.00192	CcSEcCtD
Alfentanil—Convulsion—Dexamethasone—multiple sclerosis	0.000253	0.00192	CcSEcCtD
Alfentanil—Convulsion—Betamethasone—multiple sclerosis	0.000253	0.00192	CcSEcCtD
Alfentanil—Hypertension—Dexamethasone—multiple sclerosis	0.000252	0.00192	CcSEcCtD
Alfentanil—Hypertension—Betamethasone—multiple sclerosis	0.000252	0.00192	CcSEcCtD
Alfentanil—Asthenia—Mitoxantrone—multiple sclerosis	0.000249	0.0019	CcSEcCtD
Alfentanil—Hypotension—Methylprednisolone—multiple sclerosis	0.000245	0.00186	CcSEcCtD
Alfentanil—Pain—Prednisolone—multiple sclerosis	0.000244	0.00186	CcSEcCtD
Alfentanil—Vision blurred—Prednisone—multiple sclerosis	0.000239	0.00182	CcSEcCtD
Alfentanil—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000238	0.00181	CcSEcCtD
Alfentanil—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000238	0.00181	CcSEcCtD
Alfentanil—Feeling abnormal—Prednisolone—multiple sclerosis	0.000235	0.00179	CcSEcCtD
Alfentanil—Visual impairment—Methotrexate—multiple sclerosis	0.000235	0.00179	CcSEcCtD
Alfentanil—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000233	0.00178	CcSEcCtD
Alfentanil—Nervous system disorder—Betamethasone—multiple sclerosis	0.000233	0.00178	CcSEcCtD
Alfentanil—Agitation—Prednisone—multiple sclerosis	0.000233	0.00178	CcSEcCtD
Alfentanil—Tachycardia—Dexamethasone—multiple sclerosis	0.000232	0.00177	CcSEcCtD
Alfentanil—Tachycardia—Betamethasone—multiple sclerosis	0.000232	0.00177	CcSEcCtD
Alfentanil—Hyperhidrosis—Betamethasone—multiple sclerosis	0.00023	0.00175	CcSEcCtD
Alfentanil—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.00023	0.00175	CcSEcCtD
Alfentanil—Eye disorder—Methotrexate—multiple sclerosis	0.000228	0.00173	CcSEcCtD
Alfentanil—Urticaria—Prednisolone—multiple sclerosis	0.000227	0.00172	CcSEcCtD
Alfentanil—Cardiac disorder—Methotrexate—multiple sclerosis	0.000226	0.00172	CcSEcCtD
Alfentanil—Fatigue—Triamcinolone—multiple sclerosis	0.000226	0.00172	CcSEcCtD
Alfentanil—Fatigue—Methylprednisolone—multiple sclerosis	0.000226	0.00172	CcSEcCtD
Alfentanil—Pain—Triamcinolone—multiple sclerosis	0.000224	0.00171	CcSEcCtD
Alfentanil—Loss of consciousness—Prednisone—multiple sclerosis	0.000223	0.0017	CcSEcCtD
Alfentanil—Hypotension—Dexamethasone—multiple sclerosis	0.000222	0.00169	CcSEcCtD
Alfentanil—Hypotension—Betamethasone—multiple sclerosis	0.000222	0.00169	CcSEcCtD
Alfentanil—Angiopathy—Methotrexate—multiple sclerosis	0.000221	0.00168	CcSEcCtD
Alfentanil—Vomiting—Mitoxantrone—multiple sclerosis	0.000221	0.00168	CcSEcCtD
Alfentanil—Immune system disorder—Methotrexate—multiple sclerosis	0.00022	0.00168	CcSEcCtD
Alfentanil—Convulsion—Prednisone—multiple sclerosis	0.00022	0.00167	CcSEcCtD
Alfentanil—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00022	0.00167	CcSEcCtD
Alfentanil—Hypertension—Prednisone—multiple sclerosis	0.000219	0.00167	CcSEcCtD
Alfentanil—Rash—Mitoxantrone—multiple sclerosis	0.000219	0.00167	CcSEcCtD
Alfentanil—Dermatitis—Mitoxantrone—multiple sclerosis	0.000219	0.00167	CcSEcCtD
Alfentanil—Chills—Methotrexate—multiple sclerosis	0.000219	0.00166	CcSEcCtD
Alfentanil—Headache—Mitoxantrone—multiple sclerosis	0.000218	0.00166	CcSEcCtD
Alfentanil—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000216	0.00164	CcSEcCtD
Alfentanil—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000216	0.00164	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000215	0.00163	CcSEcCtD
Alfentanil—Mental disorder—Methotrexate—multiple sclerosis	0.000214	0.00163	CcSEcCtD
Alfentanil—Erythema—Methotrexate—multiple sclerosis	0.000212	0.00161	CcSEcCtD
Alfentanil—Hypersensitivity—Prednisolone—multiple sclerosis	0.00021	0.0016	CcSEcCtD
Alfentanil—Urticaria—Triamcinolone—multiple sclerosis	0.000208	0.00159	CcSEcCtD
Alfentanil—Urticaria—Methylprednisolone—multiple sclerosis	0.000208	0.00158	CcSEcCtD
Alfentanil—Body temperature increased—Triamcinolone—multiple sclerosis	0.000207	0.00158	CcSEcCtD
Alfentanil—Anaphylactic shock—Prednisone—multiple sclerosis	0.000207	0.00158	CcSEcCtD
Alfentanil—Nausea—Mitoxantrone—multiple sclerosis	0.000207	0.00157	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000206	0.00156	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000206	0.00156	CcSEcCtD
Alfentanil—Fatigue—Betamethasone—multiple sclerosis	0.000205	0.00156	CcSEcCtD
Alfentanil—Fatigue—Dexamethasone—multiple sclerosis	0.000205	0.00156	CcSEcCtD
Alfentanil—Pain—Dexamethasone—multiple sclerosis	0.000204	0.00155	CcSEcCtD
Alfentanil—Pain—Betamethasone—multiple sclerosis	0.000204	0.00155	CcSEcCtD
Alfentanil—Nervous system disorder—Prednisone—multiple sclerosis	0.000203	0.00155	CcSEcCtD
Alfentanil—Tachycardia—Prednisone—multiple sclerosis	0.000202	0.00154	CcSEcCtD
Alfentanil—Skin disorder—Prednisone—multiple sclerosis	0.000201	0.00153	CcSEcCtD
Alfentanil—Hyperhidrosis—Prednisone—multiple sclerosis	0.0002	0.00152	CcSEcCtD
Alfentanil—Vision blurred—Methotrexate—multiple sclerosis	0.0002	0.00152	CcSEcCtD
Alfentanil—Feeling abnormal—Betamethasone—multiple sclerosis	0.000196	0.00149	CcSEcCtD
Alfentanil—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000196	0.00149	CcSEcCtD
Alfentanil—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000193	0.00147	CcSEcCtD
Alfentanil—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000193	0.00147	CcSEcCtD
Alfentanil—Urticaria—Dexamethasone—multiple sclerosis	0.000189	0.00144	CcSEcCtD
Alfentanil—Urticaria—Betamethasone—multiple sclerosis	0.000189	0.00144	CcSEcCtD
Alfentanil—Dizziness—Prednisolone—multiple sclerosis	0.000189	0.00144	CcSEcCtD
Alfentanil—Asthenia—Triamcinolone—multiple sclerosis	0.000188	0.00143	CcSEcCtD
Alfentanil—Body temperature increased—Dexamethasone—multiple sclerosis	0.000188	0.00143	CcSEcCtD
Alfentanil—Body temperature increased—Betamethasone—multiple sclerosis	0.000188	0.00143	CcSEcCtD
Alfentanil—Asthenia—Methylprednisolone—multiple sclerosis	0.000188	0.00143	CcSEcCtD
Alfentanil—Pruritus—Triamcinolone—multiple sclerosis	0.000186	0.00141	CcSEcCtD
Alfentanil—Cough—Methotrexate—multiple sclerosis	0.000185	0.00141	CcSEcCtD
Alfentanil—Pruritus—Methylprednisolone—multiple sclerosis	0.000185	0.00141	CcSEcCtD
Alfentanil—Convulsion—Methotrexate—multiple sclerosis	0.000184	0.0014	CcSEcCtD
Alfentanil—Rash—Prednisolone—multiple sclerosis	0.00018	0.00137	CcSEcCtD
Alfentanil—Dermatitis—Prednisolone—multiple sclerosis	0.00018	0.00137	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000179	0.00137	CcSEcCtD
Alfentanil—Fatigue—Prednisone—multiple sclerosis	0.000179	0.00136	CcSEcCtD
Alfentanil—Headache—Prednisolone—multiple sclerosis	0.000179	0.00136	CcSEcCtD
Alfentanil—Confusional state—Methotrexate—multiple sclerosis	0.000175	0.00133	CcSEcCtD
Alfentanil—Dizziness—Triamcinolone—multiple sclerosis	0.000173	0.00132	CcSEcCtD
Alfentanil—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000173	0.00132	CcSEcCtD
Alfentanil—Dizziness—Methylprednisolone—multiple sclerosis	0.000173	0.00132	CcSEcCtD
Alfentanil—Feeling abnormal—Prednisone—multiple sclerosis	0.000171	0.0013	CcSEcCtD
Alfentanil—Asthenia—Dexamethasone—multiple sclerosis	0.000171	0.0013	CcSEcCtD
Alfentanil—Asthenia—Betamethasone—multiple sclerosis	0.000171	0.0013	CcSEcCtD
Alfentanil—Nervous system disorder—Methotrexate—multiple sclerosis	0.00017	0.00129	CcSEcCtD
Alfentanil—Nausea—Prednisolone—multiple sclerosis	0.000169	0.00129	CcSEcCtD
Alfentanil—Pruritus—Betamethasone—multiple sclerosis	0.000168	0.00128	CcSEcCtD
Alfentanil—Pruritus—Dexamethasone—multiple sclerosis	0.000168	0.00128	CcSEcCtD
Alfentanil—Skin disorder—Methotrexate—multiple sclerosis	0.000168	0.00128	CcSEcCtD
Alfentanil—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000167	0.00127	CcSEcCtD
Alfentanil—Vomiting—Triamcinolone—multiple sclerosis	0.000167	0.00127	CcSEcCtD
Alfentanil—Vomiting—Methylprednisolone—multiple sclerosis	0.000166	0.00127	CcSEcCtD
Alfentanil—Rash—Triamcinolone—multiple sclerosis	0.000165	0.00126	CcSEcCtD
Alfentanil—Dermatitis—Triamcinolone—multiple sclerosis	0.000165	0.00126	CcSEcCtD
Alfentanil—Rash—Methylprednisolone—multiple sclerosis	0.000165	0.00126	CcSEcCtD
Alfentanil—Dermatitis—Methylprednisolone—multiple sclerosis	0.000165	0.00125	CcSEcCtD
Alfentanil—Urticaria—Prednisone—multiple sclerosis	0.000165	0.00125	CcSEcCtD
Alfentanil—Headache—Triamcinolone—multiple sclerosis	0.000164	0.00125	CcSEcCtD
Alfentanil—Headache—Methylprednisolone—multiple sclerosis	0.000164	0.00125	CcSEcCtD
Alfentanil—Body temperature increased—Prednisone—multiple sclerosis	0.000164	0.00125	CcSEcCtD
Alfentanil—Hypotension—Methotrexate—multiple sclerosis	0.000162	0.00123	CcSEcCtD
Alfentanil—Dizziness—Dexamethasone—multiple sclerosis	0.000157	0.0012	CcSEcCtD
Alfentanil—Dizziness—Betamethasone—multiple sclerosis	0.000157	0.0012	CcSEcCtD
Alfentanil—Nausea—Triamcinolone—multiple sclerosis	0.000156	0.00119	CcSEcCtD
Alfentanil—Nausea—Methylprednisolone—multiple sclerosis	0.000155	0.00118	CcSEcCtD
Alfentanil—Somnolence—Methotrexate—multiple sclerosis	0.000154	0.00117	CcSEcCtD
Alfentanil—Hypersensitivity—Prednisone—multiple sclerosis	0.000153	0.00116	CcSEcCtD
Alfentanil—Vomiting—Betamethasone—multiple sclerosis	0.000151	0.00115	CcSEcCtD
Alfentanil—Vomiting—Dexamethasone—multiple sclerosis	0.000151	0.00115	CcSEcCtD
Alfentanil—Rash—Betamethasone—multiple sclerosis	0.00015	0.00114	CcSEcCtD
Alfentanil—Rash—Dexamethasone—multiple sclerosis	0.00015	0.00114	CcSEcCtD
Alfentanil—Dermatitis—Dexamethasone—multiple sclerosis	0.00015	0.00114	CcSEcCtD
Alfentanil—Dermatitis—Betamethasone—multiple sclerosis	0.00015	0.00114	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00015	0.00114	CcSEcCtD
Alfentanil—Fatigue—Methotrexate—multiple sclerosis	0.000149	0.00114	CcSEcCtD
Alfentanil—Headache—Dexamethasone—multiple sclerosis	0.000149	0.00113	CcSEcCtD
Alfentanil—Headache—Betamethasone—multiple sclerosis	0.000149	0.00113	CcSEcCtD
Alfentanil—Asthenia—Prednisone—multiple sclerosis	0.000149	0.00113	CcSEcCtD
Alfentanil—Pain—Methotrexate—multiple sclerosis	0.000148	0.00113	CcSEcCtD
Alfentanil—Pruritus—Prednisone—multiple sclerosis	0.000147	0.00112	CcSEcCtD
Alfentanil—Feeling abnormal—Methotrexate—multiple sclerosis	0.000143	0.00109	CcSEcCtD
Alfentanil—Nausea—Dexamethasone—multiple sclerosis	0.000141	0.00108	CcSEcCtD
Alfentanil—Nausea—Betamethasone—multiple sclerosis	0.000141	0.00108	CcSEcCtD
Alfentanil—Urticaria—Methotrexate—multiple sclerosis	0.000138	0.00105	CcSEcCtD
Alfentanil—Dizziness—Prednisone—multiple sclerosis	0.000137	0.00104	CcSEcCtD
Alfentanil—Body temperature increased—Methotrexate—multiple sclerosis	0.000137	0.00104	CcSEcCtD
Alfentanil—Vomiting—Prednisone—multiple sclerosis	0.000132	0.001	CcSEcCtD
Alfentanil—Rash—Prednisone—multiple sclerosis	0.000131	0.000994	CcSEcCtD
Alfentanil—Dermatitis—Prednisone—multiple sclerosis	0.000131	0.000993	CcSEcCtD
Alfentanil—Headache—Prednisone—multiple sclerosis	0.00013	0.000988	CcSEcCtD
Alfentanil—Hypersensitivity—Methotrexate—multiple sclerosis	0.000128	0.000971	CcSEcCtD
Alfentanil—Asthenia—Methotrexate—multiple sclerosis	0.000124	0.000946	CcSEcCtD
Alfentanil—Nausea—Prednisone—multiple sclerosis	0.000123	0.000937	CcSEcCtD
Alfentanil—Pruritus—Methotrexate—multiple sclerosis	0.000123	0.000932	CcSEcCtD
Alfentanil—Dizziness—Methotrexate—multiple sclerosis	0.000115	0.000871	CcSEcCtD
Alfentanil—Vomiting—Methotrexate—multiple sclerosis	0.00011	0.000838	CcSEcCtD
Alfentanil—Rash—Methotrexate—multiple sclerosis	0.000109	0.000831	CcSEcCtD
Alfentanil—Dermatitis—Methotrexate—multiple sclerosis	0.000109	0.00083	CcSEcCtD
Alfentanil—Headache—Methotrexate—multiple sclerosis	0.000109	0.000826	CcSEcCtD
Alfentanil—Nausea—Methotrexate—multiple sclerosis	0.000103	0.000783	CcSEcCtD
Alfentanil—OPRM1—G alpha (i) signalling events—CXCR3—multiple sclerosis	8.11e-05	0.00322	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—GPR65—multiple sclerosis	8.11e-05	0.00322	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—PLEK—multiple sclerosis	8.1e-05	0.00322	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—IL4—multiple sclerosis	8.09e-05	0.00321	CbGpPWpGaD
Alfentanil—ALB—Vitamin B12 Metabolism—ICAM1—multiple sclerosis	7.9e-05	0.00314	CbGpPWpGaD
Alfentanil—OPRM1—G alpha (i) signalling events—CCR2—multiple sclerosis	7.89e-05	0.00314	CbGpPWpGaD
Alfentanil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	7.85e-05	0.00312	CbGpPWpGaD
Alfentanil—OPRM1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	7.8e-05	0.0031	CbGpPWpGaD
Alfentanil—OPRM1—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	7.77e-05	0.00309	CbGpPWpGaD
Alfentanil—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	7.53e-05	0.00299	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—CXCL13—multiple sclerosis	7.42e-05	0.00295	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—CCR1—multiple sclerosis	7.42e-05	0.00295	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	7.42e-05	0.00295	CbGpPWpGaD
Alfentanil—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.37e-05	0.00293	CbGpPWpGaD
Alfentanil—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	7.32e-05	0.00291	CbGpPWpGaD
Alfentanil—OPRM1—G alpha (i) signalling events—CNR1—multiple sclerosis	7.28e-05	0.00289	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	7.14e-05	0.00284	CbGpPWpGaD
Alfentanil—ALB—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	7.11e-05	0.00283	CbGpPWpGaD
Alfentanil—ALB—Vitamin B12 Metabolism—CCL2—multiple sclerosis	7.07e-05	0.00281	CbGpPWpGaD
Alfentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	6.94e-05	0.00276	CbGpPWpGaD
Alfentanil—OPRM1—TCR Signaling Pathway—CD4—multiple sclerosis	6.88e-05	0.00273	CbGpPWpGaD
Alfentanil—OPRM1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	6.76e-05	0.00269	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—MERTK—multiple sclerosis	6.76e-05	0.00269	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—CD58—multiple sclerosis	6.76e-05	0.00269	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—SELPLG—multiple sclerosis	6.76e-05	0.00269	CbGpPWpGaD
Alfentanil—OPRM1—Peptide ligand-binding receptors—CCL5—multiple sclerosis	6.69e-05	0.00266	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	6.68e-05	0.00266	CbGpPWpGaD
Alfentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	6.68e-05	0.00265	CbGpPWpGaD
Alfentanil—OPRM1—G alpha (i) signalling events—CXCL10—multiple sclerosis	6.56e-05	0.00261	CbGpPWpGaD
Alfentanil—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	6.56e-05	0.0026	CbGpPWpGaD
Alfentanil—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	6.56e-05	0.0026	CbGpPWpGaD
Alfentanil—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	6.47e-05	0.00257	CbGpPWpGaD
Alfentanil—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	6.47e-05	0.00257	CbGpPWpGaD
Alfentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	6.45e-05	0.00256	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—CD86—multiple sclerosis	6.43e-05	0.00256	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—ICAM1—multiple sclerosis	6.43e-05	0.00255	CbGpPWpGaD
Alfentanil—OPRM1—TCR Signaling Pathway—IL1B—multiple sclerosis	6.36e-05	0.00253	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—IL10—multiple sclerosis	6.31e-05	0.00251	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	6.31e-05	0.00251	CbGpPWpGaD
Alfentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	6.28e-05	0.00249	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—IL4—multiple sclerosis	6.14e-05	0.00244	CbGpPWpGaD
Alfentanil—OPRM1—Peptide ligand-binding receptors—CCR5—multiple sclerosis	6.03e-05	0.0024	CbGpPWpGaD
Alfentanil—ALB—Vitamin B12 Metabolism—IFNG—multiple sclerosis	6.01e-05	0.00239	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	6e-05	0.00239	CbGpPWpGaD
Alfentanil—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.97e-05	0.00237	CbGpPWpGaD
Alfentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	5.79e-05	0.0023	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—CCL2—multiple sclerosis	5.75e-05	0.00229	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—S1PR1—multiple sclerosis	5.68e-05	0.00226	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—FAS—multiple sclerosis	5.66e-05	0.00225	CbGpPWpGaD
Alfentanil—OPRM1—G alpha (i) signalling events—CCL5—multiple sclerosis	5.65e-05	0.00224	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	5.62e-05	0.00223	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	5.56e-05	0.00221	CbGpPWpGaD
Alfentanil—ALB—Vitamin B12 Metabolism—IL1B—multiple sclerosis	5.36e-05	0.00213	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—CCL3—multiple sclerosis	5.28e-05	0.0021	CbGpPWpGaD
Alfentanil—OPRM1—Opioid Signalling—MAPK1—multiple sclerosis	5.27e-05	0.00209	CbGpPWpGaD
Alfentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	5.21e-05	0.00207	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—S1PR1—multiple sclerosis	5.16e-05	0.00205	CbGpPWpGaD
Alfentanil—ALB—Selenium Micronutrient Network—ICAM1—multiple sclerosis	5.11e-05	0.00203	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—PTGER4—multiple sclerosis	5.09e-05	0.00202	CbGpPWpGaD
Alfentanil—OPRM1—G alpha (i) signalling events—CCR5—multiple sclerosis	5.09e-05	0.00202	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	5.08e-05	0.00202	CbGpPWpGaD
Alfentanil—ALB—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	4.97e-05	0.00198	CbGpPWpGaD
Alfentanil—OPRM1—TCR Signaling Pathway—TGFB1—multiple sclerosis	4.94e-05	0.00196	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—CXCR3—multiple sclerosis	4.91e-05	0.00195	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—IFNG—multiple sclerosis	4.89e-05	0.00194	CbGpPWpGaD
Alfentanil—OPRM1—TCR Signaling Pathway—MAPK1—multiple sclerosis	4.84e-05	0.00192	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—RGS1—multiple sclerosis	4.83e-05	0.00192	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—CCR2—multiple sclerosis	4.78e-05	0.0019	CbGpPWpGaD
Alfentanil—ALB—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	4.77e-05	0.0019	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—SRM—multiple sclerosis	4.73e-05	0.00188	CbGpPWpGaD
Alfentanil—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	4.72e-05	0.00188	CbGpPWpGaD
Alfentanil—OPRM1—Peptide ligand-binding receptors—POMC—multiple sclerosis	4.71e-05	0.00187	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—CD80—multiple sclerosis	4.69e-05	0.00187	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.66e-05	0.00185	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.66e-05	0.00185	CbGpPWpGaD
Alfentanil—OPRM1—Peptide ligand-binding receptors—CCL2—multiple sclerosis	4.61e-05	0.00183	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—GPR65—multiple sclerosis	4.58e-05	0.00182	CbGpPWpGaD
Alfentanil—ALB—Selenium Micronutrient Network—CCL2—multiple sclerosis	4.57e-05	0.00182	CbGpPWpGaD
Alfentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	4.49e-05	0.00178	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—CNR1—multiple sclerosis	4.41e-05	0.00175	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—RGS1—multiple sclerosis	4.39e-05	0.00174	CbGpPWpGaD
Alfentanil—CYP3A7—Biological oxidations—POMC—multiple sclerosis	4.39e-05	0.00174	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—IL1B—multiple sclerosis	4.36e-05	0.00173	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—IL2—multiple sclerosis	4.35e-05	0.00173	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—CCR1—multiple sclerosis	4.19e-05	0.00167	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—CXCL13—multiple sclerosis	4.19e-05	0.00167	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	4.18e-05	0.00166	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—PLEK—multiple sclerosis	4.18e-05	0.00166	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—GPR65—multiple sclerosis	4.16e-05	0.00165	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	4.06e-05	0.00161	CbGpPWpGaD
Alfentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	4.04e-05	0.00161	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—LINGO1—multiple sclerosis	4.02e-05	0.0016	CbGpPWpGaD
Alfentanil—OPRM1—G alpha (i) signalling events—POMC—multiple sclerosis	3.97e-05	0.00158	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—CXCL10—multiple sclerosis	3.97e-05	0.00158	CbGpPWpGaD
Alfentanil—ALB—Vitamin B12 Metabolism—TNF—multiple sclerosis	3.89e-05	0.00155	CbGpPWpGaD
Alfentanil—ALB—Selenium Micronutrient Network—IFNG—multiple sclerosis	3.88e-05	0.00154	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CXCL13—multiple sclerosis	3.81e-05	0.00151	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CCR1—multiple sclerosis	3.81e-05	0.00151	CbGpPWpGaD
Alfentanil—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	3.78e-05	0.0015	CbGpPWpGaD
Alfentanil—OPRM1—TCR Signaling Pathway—IL6—multiple sclerosis	3.72e-05	0.00148	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	3.71e-05	0.00147	CbGpPWpGaD
Alfentanil—ALB—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	3.61e-05	0.00144	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—TAGAP—multiple sclerosis	3.49e-05	0.00139	CbGpPWpGaD
Alfentanil—ALB—Selenium Micronutrient Network—IL1B—multiple sclerosis	3.47e-05	0.00138	CbGpPWpGaD
Alfentanil—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.42e-05	0.00136	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—SRM—multiple sclerosis	3.42e-05	0.00136	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—CCL5—multiple sclerosis	3.42e-05	0.00136	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—CYP27B1—multiple sclerosis	3.34e-05	0.00133	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—CYP24A1—multiple sclerosis	3.34e-05	0.00133	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	3.31e-05	0.00132	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—IL2—multiple sclerosis	3.3e-05	0.00131	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	3.26e-05	0.0013	CbGpPWpGaD
Alfentanil—CYP3A5—Biological oxidations—POMC—multiple sclerosis	3.17e-05	0.00126	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	3.17e-05	0.00126	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—TNF—multiple sclerosis	3.17e-05	0.00126	CbGpPWpGaD
Alfentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	3.16e-05	0.00126	CbGpPWpGaD
Alfentanil—ALB—Vitamin B12 Metabolism—IL6—multiple sclerosis	3.14e-05	0.00125	CbGpPWpGaD
Alfentanil—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	3.09e-05	0.00123	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—CCR5—multiple sclerosis	3.08e-05	0.00122	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—GPC5—multiple sclerosis	3.05e-05	0.00121	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—S1PR1—multiple sclerosis	3.05e-05	0.00121	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—GPC5—multiple sclerosis	2.97e-05	0.00118	CbGpPWpGaD
Alfentanil—ALB—Metabolism—SRM—multiple sclerosis	2.95e-05	0.00117	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—SELE—multiple sclerosis	2.94e-05	0.00117	CbGpPWpGaD
Alfentanil—ALB—Platelet degranulation—TGFB1—multiple sclerosis	2.91e-05	0.00115	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—PTGER4—multiple sclerosis	2.87e-05	0.00114	CbGpPWpGaD
Alfentanil—ALB—Transmembrane transport of small molecules—AQP4—multiple sclerosis	2.86e-05	0.00114	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	2.82e-05	0.00112	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	2.79e-05	0.00111	CbGpPWpGaD
Alfentanil—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.78e-05	0.0011	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—CXCR3—multiple sclerosis	2.78e-05	0.0011	CbGpPWpGaD
Alfentanil—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—multiple sclerosis	2.77e-05	0.0011	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CCL3—multiple sclerosis	2.71e-05	0.00108	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—CCR2—multiple sclerosis	2.7e-05	0.00107	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—PTGER4—multiple sclerosis	2.61e-05	0.00104	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—RGS1—multiple sclerosis	2.59e-05	0.00103	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—SRM—multiple sclerosis	2.58e-05	0.00103	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	2.57e-05	0.00102	CbGpPWpGaD
Alfentanil—ALB—Folate Metabolism—IL6—multiple sclerosis	2.55e-05	0.00101	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—RRM1—multiple sclerosis	2.53e-05	0.001	CbGpPWpGaD
Alfentanil—ALB—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.53e-05	0.001	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CXCR3—multiple sclerosis	2.52e-05	0.001	CbGpPWpGaD
Alfentanil—ALB—Selenium Micronutrient Network—TNF—multiple sclerosis	2.51e-05	0.000999	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	2.5e-05	0.000995	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—CNR1—multiple sclerosis	2.49e-05	0.00099	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—GPR65—multiple sclerosis	2.46e-05	0.000977	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CCR2—multiple sclerosis	2.45e-05	0.000974	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	2.41e-05	0.000958	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	2.41e-05	0.000958	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—POMC—multiple sclerosis	2.41e-05	0.000956	CbGpPWpGaD
Alfentanil—ABCB1—Allograft Rejection—TNF—multiple sclerosis	2.4e-05	0.000954	CbGpPWpGaD
Alfentanil—OPRM1—GPCR ligand binding—CCL2—multiple sclerosis	2.35e-05	0.000936	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CNR1—multiple sclerosis	2.26e-05	0.000899	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CCR1—multiple sclerosis	2.25e-05	0.000893	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CXCL13—multiple sclerosis	2.25e-05	0.000893	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—CXCL10—multiple sclerosis	2.24e-05	0.000892	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.21e-05	0.000879	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GPC5—multiple sclerosis	2.21e-05	0.000876	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—ITGA4—multiple sclerosis	2.13e-05	0.000845	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—IFNB1—multiple sclerosis	2.11e-05	0.000839	CbGpPWpGaD
Alfentanil—ALB—Metabolism—CYP27B1—multiple sclerosis	2.08e-05	0.000825	CbGpPWpGaD
Alfentanil—ALB—Metabolism—CYP24A1—multiple sclerosis	2.08e-05	0.000825	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CXCL10—multiple sclerosis	2.04e-05	0.00081	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.03e-05	0.000807	CbGpPWpGaD
Alfentanil—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	2.03e-05	0.000806	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—CCL5—multiple sclerosis	1.93e-05	0.000768	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GPC5—multiple sclerosis	1.9e-05	0.000755	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—RRM1—multiple sclerosis	1.83e-05	0.000726	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CYP27B1—multiple sclerosis	1.82e-05	0.000723	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CYP24A1—multiple sclerosis	1.82e-05	0.000723	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CCL5—multiple sclerosis	1.75e-05	0.000697	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—CCR5—multiple sclerosis	1.74e-05	0.000691	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—IL2RA—multiple sclerosis	1.72e-05	0.000681	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GPC5—multiple sclerosis	1.66e-05	0.000661	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	1.65e-05	0.000657	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CCL3—multiple sclerosis	1.6e-05	0.000637	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—SRM—multiple sclerosis	1.59e-05	0.000632	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CCR5—multiple sclerosis	1.58e-05	0.000628	CbGpPWpGaD
Alfentanil—ALB—Metabolism—RRM1—multiple sclerosis	1.57e-05	0.000625	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—IL2RA—multiple sclerosis	1.56e-05	0.000619	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PTGER4—multiple sclerosis	1.54e-05	0.000613	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PGR—multiple sclerosis	1.52e-05	0.000603	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CXCR3—multiple sclerosis	1.49e-05	0.000592	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CD28—multiple sclerosis	1.48e-05	0.000586	CbGpPWpGaD
Alfentanil—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.47e-05	0.000586	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—IL2RA—multiple sclerosis	1.45e-05	0.000577	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—BCHE—multiple sclerosis	1.45e-05	0.000577	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CCR2—multiple sclerosis	1.45e-05	0.000576	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—RRM1—multiple sclerosis	1.38e-05	0.000548	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—POMC—multiple sclerosis	1.36e-05	0.00054	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CNR1—multiple sclerosis	1.34e-05	0.000531	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.29e-05	0.000512	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.27e-05	0.000506	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.27e-05	0.000504	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.26e-05	0.000502	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.24e-05	0.000495	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—POMC—multiple sclerosis	1.24e-05	0.000491	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.22e-05	0.000485	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—CCL2—multiple sclerosis	1.21e-05	0.00048	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CXCL10—multiple sclerosis	1.2e-05	0.000478	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.19e-05	0.000471	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.12e-05	0.000445	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.12e-05	0.000445	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—TYK2—multiple sclerosis	1.1e-05	0.000436	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CD86—multiple sclerosis	1.05e-05	0.000418	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.05e-05	0.000417	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.05e-05	0.000417	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CCL5—multiple sclerosis	1.04e-05	0.000412	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.03e-05	0.000407	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—IL2—multiple sclerosis	1.01e-05	0.0004	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—SPP1—multiple sclerosis	9.6e-06	0.000381	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CCR5—multiple sclerosis	9.34e-06	0.000371	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IL2RA—multiple sclerosis	9.2e-06	0.000366	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—IL2—multiple sclerosis	9.13e-06	0.000363	CbGpPWpGaD
Alfentanil—ALB—Metabolism—BCHE—multiple sclerosis	9.04e-06	0.000359	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—APOE—multiple sclerosis	8.74e-06	0.000347	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—IL2—multiple sclerosis	8.52e-06	0.000338	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—RRM1—multiple sclerosis	8.5e-06	0.000338	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—APOE—multiple sclerosis	8.49e-06	0.000337	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	7.97e-06	0.000317	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—BCHE—multiple sclerosis	7.92e-06	0.000315	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CD80—multiple sclerosis	7.68e-06	0.000305	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—POMC—multiple sclerosis	7.5e-06	0.000298	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—POMC—multiple sclerosis	7.3e-06	0.00029	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CCL2—multiple sclerosis	7.14e-06	0.000284	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—MAPK1—multiple sclerosis	6.98e-06	0.000278	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—ALB—multiple sclerosis	6.84e-06	0.000272	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—TGFB1—multiple sclerosis	6.64e-06	0.000264	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—MAPK1—multiple sclerosis	6.52e-06	0.000259	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—TYK2—multiple sclerosis	6.48e-06	0.000258	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—APOE—multiple sclerosis	6.31e-06	0.000251	CbGpPWpGaD
Alfentanil—ALB—Metabolism—APOE—multiple sclerosis	5.44e-06	0.000216	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—POMC—multiple sclerosis	5.42e-06	0.000216	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IL2—multiple sclerosis	5.39e-06	0.000214	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—IL6—multiple sclerosis	5.37e-06	0.000213	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MMP9—multiple sclerosis	5.1e-06	0.000203	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—ALB—multiple sclerosis	4.95e-06	0.000197	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—BCHE—multiple sclerosis	4.88e-06	0.000194	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—APOE—multiple sclerosis	4.76e-06	0.000189	CbGpPWpGaD
Alfentanil—ALB—Metabolism—POMC—multiple sclerosis	4.67e-06	0.000186	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—STAT3—multiple sclerosis	4.54e-06	0.00018	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MYC—multiple sclerosis	4.22e-06	0.000168	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—TGFB1—multiple sclerosis	4.21e-06	0.000167	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MAPK1—multiple sclerosis	4.13e-06	0.000164	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—POMC—multiple sclerosis	4.09e-06	0.000163	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—ALB—multiple sclerosis	3.73e-06	0.000148	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IL6—multiple sclerosis	3.17e-06	0.000126	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—APOE—multiple sclerosis	2.94e-06	0.000117	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—POMC—multiple sclerosis	2.52e-06	0.0001	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ALB—multiple sclerosis	2.3e-06	9.14e-05	CbGpPWpGaD
